Ethris and Lonza have teamed up to develop room-temperature stable, spray-dried mRNA vaccines for respiratory diseases. This collaboration aims to create mucosal delivery formulations, offering a promising new approach to combat respiratory illnesses.
JFE Steel, Mitsubishi Gas Chemical, and Mitsubishi Chemical collaborate to develop a carbon recycling supply chain at Mizushima Complex.
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
Ecovyst, a provider of advanced materials, specialty catalysts, sulfuric acid and regeneration services, and ChiralVision, a developer of biocatalysis-based technologies have signed a Memorandum of Understanding (MOU) for a partnership in the field of enzyme immobilization.
In a move to promote innovation and sustainability in the materials industry, Syensqo has entered into a partnership with the Jean-Marie Lehn Foundation.
In collaboration with Shell, COAC has implemented the Smart Equipment Passport (SEP), a solution to create digital identities of equipment that can be used to exchange information with internal and external users safely and securely.
Aurigene Pharmaceutical Services, the CRDMO arm of India-based Dr. Reddy’s, has signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, a US-based company with a proprietary platform that helps target cytoskeletal proteins of parasites, for the development and commercialization of an affordable anti-malarial drug in in the US, Europe, and in low and middle-income countries.
Honeywell and Spanish energy and petrochemicals group Repsol are collaborating to create new production pathways for biofuels and circular materials. The two companies will also explore the possible integration of these methods into Repsol’s existing facilities.
GSK and innovation company Flagship Pioneering have entered a collaboration to develop a portfolio of new medicines and vaccines, starting in respiratory and immunology. Flagship’s ecosystem comprises 40 bioplatform companies, including Moderna.
Syensqo, a global provider of advanced materials, and Orbex, a leader in private space launch services, recently signed a strategic collaboration agreement to develop and deploy next-generation aerospace technologies.
Quantro Therapeutics, which focuses on transcription factors targeting cancer treatments, announced that it has reached a key milestone in its joint R&D program with Boehringer Ingelheim.
US chemical group Celanese and Germany’s Secarna Pharmaceuticals, an antisense drug discovery and development company, entered a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
Syngenta Group announced important collaborations following the launch of its innovation accelerator platform Shoots by Syngenta in 2023. These collaborations, which connect expertise across industries and sectors, are aimed at making possible novel solutions to agricultural challenges more quickly and efficiently.
Isomorphic Labs announced strategic collaborations with leading pharmaceutical companies, Eli Lilly and Company and Novartis. These partnerships have the potential to be worth nearly €2.75 billion ($3 billion) to Isomorphic Labs, excluding any royalties that may result from future drug sales. Both collaborations are multi-target, focused on small molecules, and include a combination of upfront and milestone payments.
